



HOIST Corporation

Representative Director: Chihaya Kakinuma

Executive Officer, Head of Management Division, CFO: Koji Abe

(Representative phone number: 072-707-2760)

HOIST Corporation announces the publication of a novel method to generate patient-derived xenograft (PDX) models from cryopreserved cancer tissues

- A paper has been published in Journal of Toxicological Pathology
- The paper concerns a new method to generate patient-derived xenograft models

Osaka, Japan – 30 Apr 2025 HOIST Corporation today announced the publication of a paper in Journal of Toxicological Pathology. The paper details a novel method to generate patient-derived xenograft (PDX) models from cryopreserved cancer tissues which demonstrates improved proliferation after transplantation.

We shall be continuing to utilize our drug discovery platform technology, PDC/PDX, to further advance research and development of our pipeline.

About HOIST Corporation

Founded in 2019, HOIST Corporation is a clinical stage biotechnology company based in Osaka, Japan. Focusing on unmet needs in oncology, HOIST Corporation is exploring new approaches to cancer treatment.

About PDC/PDX Technology

Patient derived cells (PDC) and Patient derived xenografts (PDX) represent the next generation in cancer research, and allows for a model that more accurately mirrors the characteristics of the tumor compared with cancer cell lines.

Please refer to the following page regarding the details for our proprietary PDC/PDX technology:
<https://hoist-jp.com/en/home/technical-info/#pdx>

*Please refer to the following website for the details of the publication:
https://www.jstage.jst.go.jp/article/tox/38/2/38_2024-0054/_article/-char/en